Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Construction in Progress (2023 - 2024)

HCW Biologics (HCWB) has disclosed Construction in Progress for 2 consecutive years, with $13.5 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Construction in Progress rose 29.81% year-over-year to $13.5 million, compared with a TTM value of $13.5 million through Dec 2024, up 29.81%, and an annual FY2024 reading of $13.5 million, up 29.81% over the prior year.
  • Construction in Progress was $13.5 million for Q4 2024 at HCW Biologics, up from $10.4 million in the prior quarter.
  • Across five years, Construction in Progress topped out at $13.5 million in Q4 2024 and bottomed at $10.4 million in Q4 2023.